These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6896252)

  • 1. [Indications for and methods of allopurinol-benzbromarone combination therapy in the treatment of hyperuricemic metabolic disorders].
    Heidelmann G; Burck G; Dauterstedt W; Heinrich JJ; Ohlmer R
    Z Arztl Fortbild (Jena); 1982 Mar; 76(5):177-81. PubMed ID: 6896252
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F
    Fortschr Med; 1983 May; 101(20):953-9. PubMed ID: 6873850
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 8. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
    Mertz DP; Borner K
    Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness and tolerance of long-term uricosuric treatment].
    Berg H
    Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of gout with alternate-day hypo-uricaemic drugs.
    Nishizawa T; Nishida Y; Masuda T; Akaoka I
    Rheumatol Rehabil; 1978 Aug; 17(3):143-9. PubMed ID: 705170
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
    Inokuchi T; Tsutsumi Z; Takahashi S; Ka T; Yamamoto A; Moriwaki Y; Masuzaki H; Yamamoto T
    Horm Metab Res; 2009 Apr; 41(4):327-32. PubMed ID: 19048458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
    Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic gout. Case report of a severe course of disease].
    Boxberger F; Harsch IA; Brueckl WM; Hautmann M; Baum U; Hahn EG; Wein A
    Med Klin (Munich); 2003 Nov; 98(11):646-7. PubMed ID: 14631540
    [No Abstract]   [Full Text] [Related]  

  • 15. [Allopurinol-benzbromarone combination. Renal excretion of various ions during high-dosage therapy using an allopurinol-benzbromarone combination].
    Mertz DP; Göhmann E
    ZFA (Stuttgart); 1978 May; 54(14):811-5. PubMed ID: 664826
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 18. [Isolated or combined drug therapy of hyperuricemia?].
    Mertz DP
    Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.